TABLE 2.

Drug susceptibility test results of phase I^a

Drug and concn (μg/ml)	No. of strains for which the indicated concn is the MIC						Total no. (%) of tests
	Site 1		Site 2		Site 3
	MGIT	460	MGIT	460	MGIT	460	MGIT	460
Amikacin
≤0.5	10	10	10	10	10	10	30 (100)	30 (100)
1.0	0	0	0	0	0	0	0	0
2.0	0	0	0	0	0	0	0	0
Capreomycin
0.625	1	3	9	10	0	10	10 (33.3)	23 (76.7)
1.25	8	7	1	0	10	0	19 (63.3)	7 (23.3)
2.5	1	0	0	0	0	0	1 (3.3)	0
Ethionamide
≤0.625	3	5	7	8	6	8	16 (53.3)	21 (70.0)
1.25	4	2	0	1	2	1	6 (20.0)	4 (13.3)
2.5	2	3	1	0	1	0	4 (13.3)	3 (10.0)
>2.5	1	0	2	1	1	1	4 (13.3)	2 (6.7)
Ofloxacin
≤1.0	10	10	10	10	10	10	30 (100)	30 (100)
2.0	0	0	0	0	0	0	0	0
4.0	0	0	0	0	0	0	0	0
Rifabutin
≤0.25	10	10	10	10	10	10	30 (100)	30 (100)
0.5	0	0	0	0	0	0	0	0
1.0	0	0	0	0	0	0	0	0
Linezolid
≤0.5	5	5	5	10	10	8b	20 (66.7)b	23 (76.7)b
1.0	5	5	4	0	0	1	9 (30.0)	6 (20.0)
2.0	0	0	1	0	0	0	1 (3.3)	0

^aTen strains were tested. MGIT, MGIT 960; 460, BACTEC 460.

^bResults for one test missing.